Skip to main content

Advertisement

Table 2 Rating scale assessments

From: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Rating scale 
UPDRS Part I (mentation, behavior and mood); mean ± SD
 Baseline (n = 477)2.3 ± 2.1
 3 months (n = 393)1.9 ± 1.9
 Change from baseline (n = 393)− 0.3 ± 1.5
UPDRS Part II (ADL during OFF); mean ± SD
 Baseline (n = 476)17.1 ± 7.0
 3 months (n = 391)13.9 ± 6.8
 Change from baseline (n = 391)− 3.0 ± 4.6
P value vs. baseline< 0.0001
UPDRS Part III (motor scores during ON); mean ± SD
 Baseline (n = 477)26.5 ± 12.1
 3 months (n = 393)21.5 ± 11.0
 Change from baseline (n = 393)− 4.6 ± 8.1
P value vs. baseline< 0.0001
UPDRS Total scores (Part II + III); mean ± SD
 Baseline (n = 477)37.5 ± 16.9
 3 months (n = 393)30.5 ± 15.2
 Change from baseline (n = 393)− 6.4 ± 10.4
P value vs. baseline< 0.0001
UPDRS Part IV (complications of therapy); mean ± SD
 Baseline (n = 475)5.2 ± 2.6
 3 months (n = 391)4.2 ± 2.4
 Change from baseline (n = 391)− 0.8 ± 1.9
PDQ-8 Total Score; mean ± SD
 Baseline (n = 476)29.2 ± 16.4
 3 months (n = 393)25.2 ± 15.8
 Change from baseline (n = 393)− 3.4 ± 12.8
P value vs. baseline< 0.0001
NMSS Score; mean ± SD
 Baseline (n = 477)44.6 ± 30.3
 3 months (n = 393)37.0 ± 26.7
 Change from baseline (n = 393)− 6.8 ± 19.7
P value vs. baseline< 0.0001
  1. NMSS Non-motor symptom scale, UPDRS Unified Parkinson’s Disease Rating Scale, PDQ-8 Parkinson’s Disease Questionnaire